WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |

Search International and National Patent Collections
World Intellectual Property Organization
Machine translation
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2006/016715    International Application No.:    PCT/JP2005/015031
Publication Date: 16.02.2006 International Filing Date: 11.08.2005
C07D 487/04 (2006.01), A61K 31/519 (2006.01), A61P 3/04 (2006.01), A61P 3/10 (2006.01), A61P 9/00 (2006.01), A61P 9/10 (2006.01), A61P 11/00 (2006.01), A61P 17/06 (2006.01), A61P 19/02 (2006.01), A61P 19/10 (2006.01), A61P 25/28 (2006.01), A61P 29/00 (2006.01), A61P 31/04 (2006.01), A61P 35/00 (2006.01), A61P 37/06 (2006.01)
Applicants: TEIJIN PHARMA LIMITED [JP/JP]; 1-1, Uchisaiwaicho 2-chome, Chiyoda-ku, Tokyo 1000011 (JP) (For All Designated States Except US).
KOSUGI, Tomomi [JP/JP]; (JP) (For US Only).
IMAI, Minoru [JP/JP]; (JP) (For US Only).
MAKINO, Hiroaki [JP/JP]; (JP) (For US Only).
TAKAKUWA, Mika [JP/JP]; (JP) (For US Only).
UNOKI, Gen [JP/JP]; (JP) (For US Only).
KATAOKA, Kenichiro [JP/JP]; (JP) (For US Only).
MITCHELL, Dale, Robert [GB/GB]; (GB) (For US Only).
SIMPSON, Donald, James [GB/GB]; (GB) (For US Only).
HARRIS, Clifford, John [GB/GB]; (GB) (For US Only).
LE, Joelle [GB/GB]; (GB) (For US Only).
YAMAKOSHI, Yuko [JP/JP]; (JP) (For US Only)
Inventors: KOSUGI, Tomomi; (JP).
IMAI, Minoru; (JP).
MAKINO, Hiroaki; (JP).
UNOKI, Gen; (JP).
KATAOKA, Kenichiro; (JP).
MITCHELL, Dale, Robert; (GB).
SIMPSON, Donald, James; (GB).
HARRIS, Clifford, John; (GB).
LE, Joelle; (GB).
Agent: MIHARA, Hideko; c/o Teijin Intellectual Property Center Limited 1-1, Uchisaiwaicho 2-chome Chiyoda-ku, Tokyo 1000011 (JP)
Priority Data:
2004-236035 13.08.2004 JP
(JA) ピラゾロ[1,5-a]ピリミジン誘導体
Abstract: front page image
(EN)Pyrazolo[1,5-a]pyrimidine derivatives of the formula (I) and pharmaceutically acceptable salts thereof exhibit excellent MAPKAP-K2 inhibiting activity. Consequently, pharmaceutical products comprising these as active ingredients are expected to be effective in the prevention or treatment of MAPKAP-K2 mediated diseases, for example, inflammatory diseases, autoimmune diseases, osteoclastic disorder, cancer and/or tumor growth.
(FR)L'invention concerne des dérivés de la pyrazolo[1,5-a]pyrimidine de formule (I) et des sels pharmaceutiquement acceptables de celle-ci et présentant une excellente activité d'inhibition de la MAPKAP-K2. Par conséquent, les produits pharmaceutiques contenant ceux-ci comme ingrédients actifs sont supposés être efficaces dans la prévention ou le traitement des maladies médiées par MAPKAP-K2, par exemple, les maladies inflammatoires, les maladies auto-immunes, l’affection ostéoclastique, les cancers et/ou la croissance l tumorale.
(JA) 式(Ⅰ)で表わされるピラゾロ[1,5−a]ピリミジン誘導体とそれらの医薬上許容される塩は、優れたMAPKAP−K2阻害活性を示す。従って、有効成分としてこの化合物を含む医薬品は、例えば炎症性疾患、自己免疫性疾患、破壊性骨障害、癌および/または腫瘍成長などのMAPKAP−K2媒介性疾患の治療または予防に有用であることが期待される。
Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: Japanese (JA)
Filing Language: Japanese (JA)